CSPG4 and melanoma: As target cells, either the human TxB cell hybridoma T2.A1 (HLA-A2+, CSPG4−, gp100−) or the human melanoma cell line A375M (HLA-A2+, CSPG4+, gp100−), both either unpulsed or pulsed with the HLA-A2-restricted peptide gp100280–288, were used.